Pharmacological attenuation of apoptosis in reoxygenated endothelial cells

BRX-235 (Iroxanadine), a novel drug developed by Biorex (Hungary), was previously characterized as a vasculoprotector against atherosclerosis, an activator of p38 kinase, and an enhancer of stress-responsive heat shock protein (Hsp) expression. The present data demonstrate that BRX-235 may improve survival of vascular endothelial cells (ECs) following ischemia/reperfusion stress. ECs cultured from human umbilical veins were exposed to hypoxia/reoxygenation to mimic ischemia/reperfusion. Caspase activation and apoptosis were monitored in the reoxygenated cells. Addition of BRX-235 (0.1–1 M) to culture medium prior to hypoxia or at start of reoxygenation significantly reduced the caspase-dependent apoptosis. The cytoprotection conferred by the pre-hypoxic drug administration was sensitive to quercetin and seems to be based on enhanced Hsp accumulation in stressed ECs. In the case of post-hypoxic drug administration, the cytoprotection was strongly inhibited by SB202190 and SB203580 and appears to be associated with enhanced p38 kinase activation in reoxygenated ECs.Received 12 May 2004; received after revision 7 September 2004; accepted 24 September 2004     

铑催化剂上CO的吸附态及其加氢反应

用红外光谱法测定表明：各种硅胶负载仲进型铑催化剂上，线ＣＯ／桥ＣＯ红外吸收强度比值与金属助剂（Ｍ）的关系变化顺序为（５０：１）（Ｒｈ－Ｍｎ）〉（２２：１）（Ｒｈ－Ｌｉ）〉（９．１：１）（Ｒｈ－Ｍｎ－Ｆｅ－Ｌｉ）〉（３．５：１）（Ｒｈ－Ｆｅ）〉２．８：１）（Ｒｈ）。在各种Ｒｈ－Ｍ／ＳｉＯ２催化剂上，线、桥ＣＯ吸附态的加氢原位ＦＴＩＲ跟踪实验表明：随着加氢的进行，线ＣＯ／桥ＣＯ吸收强度比值均逐渐减少…